• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Keswani Sanjay Chandru

    6/4/25 5:34:40 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Keswani Sanjay Chandru

    (Last) (First) (Middle)
    6027 EDGEWOOD BEND CT.

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/02/2025
    3. Issuer Name and Ticker or Trading Symbol
    NEUROCRINE BIOSCIENCES INC [ NBIX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Darin Lippoldt, Attorney-in-Fact 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NBIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

    SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately o

    8/6/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Reports Second Quarter 2025 Financial Results

    Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO, July 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. "As we begin

    7/30/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

    Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (NASDAQ:NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing

    7/15/25 9:00:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Neurocrine Biosciences with a new price target

    Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

    7/21/25 8:37:42 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman initiated coverage on Neurocrine Biosciences with a new price target

    Goldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00

    7/10/25 8:58:47 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences upgraded by Needham with a new price target

    Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

    4/15/25 7:52:35 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Neurocrine Biosciences Inc.

    10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    7/30/25 4:04:04 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    7/30/25 4:02:54 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

    5/30/25 4:05:10 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gorman Kevin Charles sold $13,440,281 worth of shares (106,322 units at $126.41) and exercised 106,322 shares at a strike of $35.99 (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    8/11/25 4:55:16 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Onyia Jude gifted 3,116 shares, decreasing direct ownership by 17% to 15,173 units (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    8/7/25 4:29:30 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Delaet Ingrid exercised 457 shares at a strike of $79.02 and sold $61,695 worth of shares (457 units at $135.00) (SEC Form 4)

    4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    7/11/25 5:15:12 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Financials

    Live finance-specific insights

    View All

    Neurocrine Biosciences Reports Second Quarter 2025 Financial Results

    Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO, July 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. "As we begin

    7/30/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

    Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

    7/9/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

    INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

    5/5/25 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    View All

    Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

    SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

    6/9/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

    Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

    4/4/25 8:00:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurocrine Biosciences Inc.

    SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    10/17/24 9:54:01 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/9/23 11:27:44 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

    SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    2/14/22 2:34:19 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care